Register Login

Blog

July 2025 QQ: Hemophilia Rebalancing Therapy

Our July 2025 Quick Question asked, “Which is a hemophilia ‘rebalancing’ therapeutic?” The question attracted a modest 22 participants, perhaps an indication that rebalancing therapy was only FDA-approved in 2025 and awaits approval in Canada and Europe. Here are your responses… Valoctocogene roxaparvovec-rvox (ROCTAVIAN) 3 (14%) Efanesoctocog alfa (ALTUVIIIO) 1 (4%) Emicizumab (HemLibra) 7 (32%) […]
read more